Financial Snapshot

Revenue
$3.900M
TTM
Gross Margin
27.27%
TTM
Net Earnings
-$9.033M
TTM
Current Assets
Q1 2024
Current Liabilities
Q1 2024
Current Ratio
159.89%
Q1 2024
Total Assets
Q1 2024
Total Liabilities
Q1 2024
Book Value
$13.93M
Q1 2024
Cash
Q1 2024
P/E
-0.1443
Nov 29, 2024 EST
Free Cash Flow
-$2.087M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $1.928M $1.972M $2.602M $4.778M $5.160M $7.010M $7.020M $4.880M $3.720M
YoY Change -2.19% -24.23% -45.53% -7.41% -26.39% -0.14% 43.85% 31.18%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $1.928M $1.972M $2.602M $4.778M $5.160M $7.010M $7.020M $4.880M $3.720M
Cost Of Revenue $1.375M $1.545M $1.351M $1.938M $2.460M $2.400M $3.620M $2.570M $2.920M
Gross Profit $554.0K $426.3K $1.252M $2.840M $2.700M $4.610M $3.400M $2.310M $790.0K
Gross Profit Margin 28.73% 21.62% 48.1% 59.44% 52.33% 65.76% 48.43% 47.34% 21.24%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $3.069M $6.034M $6.441M $5.037M $4.040M $2.840M $1.770M $710.0K $580.0K
YoY Change -49.13% -6.33% 27.89% 24.67% 42.25% 60.45% 149.3% 22.41%
% of Gross Profit 554.03% 1415.48% 514.63% 177.37% 149.63% 61.61% 52.06% 30.74% 73.42%
Research & Development $184.2K $200.7K $367.0K
YoY Change -8.23% -45.31%
% of Gross Profit 33.25% 47.09% 29.32%
Depreciation & Amortization $203.2K $250.2K $320.0K $345.4K $330.0K $180.0K $130.0K $90.00K $90.00K
YoY Change -18.75% -21.83% -7.35% 4.67% 83.33% 38.46% 44.44% 0.0%
% of Gross Profit 36.69% 58.69% 25.57% 12.16% 12.22% 3.9% 3.82% 3.9% 11.39%
Operating Expenses $3.069M $6.034M $6.441M $5.037M $4.040M $2.840M $1.770M $710.0K $590.0K
YoY Change -49.13% -6.33% 27.89% 24.67% 42.25% 60.45% 149.3% 20.34%
Operating Profit -$2.515M -$5.608M -$5.190M -$2.197M -$1.340M $1.770M $1.630M $1.600M $200.0K
YoY Change -55.15% 8.05% 136.21% 63.96% -175.71% 8.59% 1.88% 700.0%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense -$544.3K $476.8K -$36.70K -$1.615M -$3.350M -$10.00K $0.00 -$40.00K -$50.00K
YoY Change -214.16% -1399.12% -97.73% -51.78% 33400.0% -100.0% -20.0%
% of Operating Profit -0.56% 0.0% -2.5% -25.0%
Other Income/Expense, Net -$583.3K -$327.3K -$181.6K $871.7K -$70.00K $30.00K $0.00 $20.00K $30.00K
YoY Change 78.24% 80.23% -120.83% -1345.21% -333.33% -100.0% -33.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$3.099M -$5.935M -$5.408M -$2.941M -$10.39M $1.790M $1.630M $1.580M $190.0K
YoY Change -47.79% 9.74% 83.89% -71.7% -680.45% 9.82% 3.16% 731.58%
Income Tax $328.2K -$192.7K -$100.0K $250.0K $440.0K $400.0K $50.00K
% Of Pretax Income 13.97% 26.99% 25.32% 26.32%
Net Earnings -$3.099M -$5.935M -$5.736M -$2.748M -$10.29M $1.540M $1.190M $1.190M $140.0K
YoY Change -47.79% 3.46% 108.72% -73.29% -768.18% 29.41% 0.0% 750.0%
Net Earnings / Revenue -160.67% -301.0% -220.43% -57.52% -199.42% 21.97% 16.95% 24.39% 3.76%
Basic Earnings Per Share -$3.57 -$0.89 -$5.52 -$3.82
Diluted Earnings Per Share -$3.57 -$0.89 -$5.517M -$3.819M -$1.665M $299.6K $200.3K $200.3K $23.57K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $12.07M $17.37M $15.52M $13.33M $7.290M $9.130M $560.0K $70.00K $10.00K
YoY Change -30.5% 11.88% 16.44% 82.89% -20.15% 1530.36% 700.0% 600.0%
Cash & Equivalents $12.07M $17.37M $15.52M $13.33M $7.290M $9.130M $560.0K $70.00K $10.00K
Short-Term Investments
Other Short-Term Assets $21.74K $276.9K $384.5K $2.380M $1.750M $1.190M $990.0K $180.0K $640.0K
YoY Change -92.15% -27.98% -83.84% 36.02% 47.06% 20.2% 450.0% -71.88%
Inventory $794.9K $531.3K $1.018M $859.7K $890.0K $1.010M $1.270M $890.0K $1.350M
Prepaid Expenses
Receivables $845.9K $1.345M $3.333M $4.507M $3.820M $4.180M $2.600M $2.740M $1.950M
Other Receivables $500.5K $0.00 $2.192M $2.153M $5.880M $80.00K $690.0K $1.030M $1.780M
Total Short-Term Assets $14.23M $19.52M $22.45M $23.23M $19.64M $15.59M $6.100M $4.910M $5.730M
YoY Change -27.09% -13.05% -3.36% 18.3% 25.98% 155.57% 24.24% -14.31%
Property, Plant & Equipment $564.7K $1.268M $1.591M $1.789M $1.900M $1.810M $1.490M $490.0K $430.0K
YoY Change -55.48% -20.28% -11.08% -5.84% 4.97% 21.48% 204.08% 13.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.310M $8.737M $9.465M $9.479M $110.0K $10.00K $10.00K $0.00
YoY Change -4.88% -7.69% -0.15% 8517.48% 1000.0% 0.0%
Total Long-Term Assets $8.894M $10.03M $11.09M $11.31M $2.060M $1.880M $1.560M $520.0K $480.0K
YoY Change -11.35% -9.57% -1.94% 449.23% 9.57% 20.51% 200.0% 8.33%
Total Assets $23.13M $29.55M $33.55M $34.55M $21.70M $17.47M $7.660M $5.430M $6.210M
YoY Change
Accounts Payable $1.280M $1.378M $1.482M $1.456M $1.940M $1.690M $2.410M $1.260M $2.890M
YoY Change -7.14% -7.04% 1.77% -24.93% 14.79% -29.88% 91.27% -56.4%
Accrued Expenses $1.498M $1.120M $969.8K $1.168M $640.0K $490.0K $160.0K $150.0K $180.0K
YoY Change 33.81% 15.46% -16.94% 82.42% 30.61% 206.25% 6.67% -16.67%
Deferred Revenue
YoY Change
Short-Term Debt $493.1K $167.5K $0.00 $0.00 $0.00 $230.0K $390.0K $300.0K $380.0K
YoY Change 194.45% -100.0% -41.03% 30.0% -21.05%
Long-Term Debt Due $1.801M $3.165M $2.046M $37.12K $6.690M $30.00K
YoY Change -43.09% 54.68% 5412.8% -99.45% 22200.0%
Total Short-Term Liabilities $8.902M $14.50M $17.12M $18.58M $12.26M $6.320M $4.370M $3.580M $5.460M
YoY Change -38.59% -15.33% -7.85% 51.55% 93.99% 44.62% 22.07% -34.43%
Long-Term Debt $117.1K $117.9K $0.00 $6.290K $40.00K $40.00K $0.00 $0.00 $0.00
YoY Change -0.62% -100.0% -84.28% 0.0%
Other Long-Term Liabilities $177.5K $248.0K
YoY Change -28.4%
Total Long-Term Liabilities $294.7K $365.8K $0.00 $6.290K $40.00K $40.00K $0.00 $0.00 $0.00
YoY Change -19.45% -100.0% -84.28% 0.0%
Total Liabilities $9.197M $14.86M $17.12M $18.59M $12.30M $6.360M $4.370M $3.580M $5.460M
YoY Change -38.12% -13.19% -7.88% 51.11% 93.4% 45.54% 22.07% -34.43%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 867.4K shares 6.674M shares 1.040M shares 719.5K shares
Diluted Shares Outstanding 867.4K shares 6.674M shares 1.040M shares 719.5K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $1.3039 Million

About China SXT Pharmaceuticals, Inc.

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). The company is headquartered in Taizhou, Jiangsu and currently employs 75 full-time employees. The company went IPO on 2019-01-04. The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

Industry: Pharmaceutical Preparations Peers: CHINA PHARMA HOLDINGS, INC. SUNWIN STEVIA INTERNATIONAL, INC. BGM Group Ltd. Universe Pharmaceuticals INC